TWINBEECH CAPITAL LP - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 160 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.

Quarter-by-quarter ownership
TWINBEECH CAPITAL LP ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q3 2023$1,722,284
+176.2%
62,583
+240.6%
0.03%
+175.0%
Q2 2023$623,498
-60.7%
18,376
-58.3%
0.01%
-62.5%
Q1 2023$1,585,567
+15.2%
44,068
-10.0%
0.03%
-11.1%
Q3 2022$1,376,000
+309.5%
48,939
+395.9%
0.04%
+140.0%
Q1 2022$336,000
+21.7%
9,868
+38.1%
0.02%
-6.2%
Q4 2021$276,0007,1440.02%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q3 2022
NameSharesValueWeighting ↓
Kynam Capital Management, LP 1,605,390$71,552,23210.98%
Octagon Capital Advisors LP 761,398$33,935,5095.28%
TSP Capital Management Group, LLC 269,895$12,029,2254.50%
Redmile Group, LLC 1,977,451$88,134,9913.60%
COMMODORE CAPITAL LP 495,823$22,0993.33%
Tri Locum Partners LP 176,109$7,849,0003.18%
ACUTA CAPITAL PARTNERS, LLC 115,000$5,125,5503.15%
Ikarian Capital, LLC 267,476$11,921,4062.88%
RTW INVESTMENTS, LP 3,084,215$137,463,4632.81%
Eversept Partners, LP 558,774$24,904,5572.18%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders